Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
7.01
0.00 (0.00%)
At close: Sep 8, 2025, 4:00 PM
6.87
-0.14 (-2.00%)
After-hours: Sep 8, 2025, 5:26 PM EDT
Journey Medical Stock Forecast
Stock Price Forecast
The 3 analysts that cover Journey Medical stock have a consensus rating of "Strong Buy" and an average price target of $12.67, which forecasts a 80.74% increase in the stock price over the next year. The lowest target is $12 and the highest is $13.
Price Target: $12.67 (+80.74%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Journey Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +85.45% | Aug 25, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $9 → $13 | Strong Buy | Maintains | $9 → $13 | +85.45% | Aug 13, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +71.18% | Jul 30, 2025 |
| Lake Street | Lake Street | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +28.39% | Sep 6, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +56.92% | Jun 28, 2024 |
Financial Forecast
Revenue This Year
71.91M
from 56.13M
Increased by 28.10%
Revenue Next Year
110.62M
from 71.91M
Increased by 53.84%
EPS This Year
-0.29
from -0.72
EPS Next Year
0.81
from -0.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 79.9M | 134.4M | |
| Avg | 71.9M | 110.6M | |
| Low | 65.7M | 90.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 42.3% | 86.8% | |
| Avg | 28.1% | 53.8% | |
| Low | 17.0% | 25.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.12 | 2.10 | |
| Avg | -0.29 | 0.81 | |
| Low | -0.40 | 0.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.